<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="16265">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00053365</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-02512</org_study_id>
    <secondary_id>NCI-2012-02512</secondary_id>
    <secondary_id>CDR0000269484</secondary_id>
    <secondary_id>GOG-0146O</secondary_id>
    <secondary_id>GOG-0146O</secondary_id>
    <secondary_id>U10CA027469</secondary_id>
    <nct_id>NCT00053365</nct_id>
  </id_info>
  <brief_title>Irofulven in Treating Patients With Recurrent or Persistent Ovarian Epithelial or Primary Peritoneal Cancer</brief_title>
  <official_title>A Phase II Evaluation Of Irofulven (IND #55804, NSC #683863) In The Treatment Of Recurrent Or Persistent Platinium-Sensitive Ovarian Or Primary Peritoneal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase II trial to study the effectiveness of irofulven in treating patients who have
      recurrent or persistent ovarian epithelial cancer or primary peritoneal cancer. Drugs used
      in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or
      die.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      I. Determine the antitumor activity of irofulven in patients with persistent or recurrent
      platinum-sensitive ovarian epithelial or primary peritoneal cancer.

      II. Determine the toxicity of this drug in these patients.

      OUTLINE:

      Patients receive irofulven IV over 30 minutes on days 1 and 8. Courses repeat every 21 days
      in the absence of unacceptable toxicity or disease progression.

      Patients are followed at approximately 30 days, every 3 months for 2 years, and then every 6
      months for 3 years.

      PROJECTED ACCRUAL: Approximately 22-60 patients will be accrued for this study within at
      least 6 months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2003</start_date>
  <completion_date type="Actual">July 2010</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Tumor Response</measure>
    <time_frame>From entry into study until documented progression or death, assessed up to 5 years.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Per Gynecologic Oncology Group(GOG) Response Evaluation Criteria in Solid Tumors(RECIST) Criteria: Complete Response is disappearance of all target and non-target lesions; Partial Response is at least a 30% decrease in the sum of longest dimensions (LD) of all target measurable dimensions; Increasing Disease is at least a 20% increase in the sum of LD of target lesions taking as reference the smallest sum LD or the appearance of new lesions within 8 weeks of study entry.
Response is to be evaluated every 42 days for the first 6 months and every 6 months thereafter while the patient is receiving study treatment, then every 3 months for 2 years and every 6 months for the next 3 years until documented progression or death.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency and Severity of Observed Adverse Events, Graded According to the National Cancer Institute Common Toxicity Criteria (NCI CTC) v2.0</measure>
    <time_frame>Up to 5 years</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival and Progression-free Survival</measure>
    <time_frame>From entry into study to death or date of last contact, assessed up to 5 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Per Gynecologic Oncology Group(GOG) Response Evaluation Criteria in Solid Tumors(RECIST) Criteria, progression is defined as at least a 20% increase in the sum of longest dimesions(LD) of target lesions taking as reference the smallest sum LD or the appearance of new lesions within 8 weeks of study entry.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Progression-free Survival</measure>
    <time_frame>From study entry until disease progression, death or date of last contact, assessed up to 5 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">61</enrollment>
  <condition>Primary Peritoneal Cavity Cancer</condition>
  <condition>Recurrent Ovarian Epithelial Cancer</condition>
  <arm_group>
    <arm_group_label>Treatment (irofulven)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive irofulven IV over 30 minutes on days 1 and 8. Courses repeat every 21 days in the absence of unacceptable toxicity or disease progression.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>irofulven</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (irofulven)</arm_group_label>
    <other_name>6-hydroxymethylacylfulvene</other_name>
    <other_name>HMAF</other_name>
    <other_name>MGI 114</other_name>
    <other_name>MGI-114</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed ovarian epithelial or primary peritoneal carcinoma

               -  Recurrent or persistent disease

          -  At least 1 unidimensionally measurable target lesion* defined as:

               -  At least 20 mm by conventional techniques OR at least 10 mm by spiral CT scan

          -  Must have received 1 prior platinum-based chemotherapeutic regimen containing
             carboplatin, cisplatin, or another organoplatinum compound for primary disease

               -  Initial treatment may have included high-dose, consolidation, or extended
                  therapy administered after surgical or non-surgical assessment

               -  Patients who have not received prior paclitaxel may receive a second regimen
                  containing paclitaxel

          -  Ineligible for a higher priority GOG protocol (e.g., any active phase III GOG
             protocol for the same patient population)

          -  Platinum-sensitive disease

               -  Platinum-free interval** of more than 6 months, but less than 12 months
                  duration, with no clinical evidence of progressive disease after response to
                  platinum

          -  Performance status - GOG 0-2 for patients who received 1 prior therapy regimen

          -  Performance status - GOG 0-1 for patients who received 2 prior therapy regimens

          -  Absolute neutrophil count at least 1,500/mm^3

          -  Platelet count at least 100,000/mm^3

          -  Bilirubin no greater than 1.5 times upper limit of normal (ULN)

          -  SGOT no greater than 2.5 times ULN

          -  Alkaline phosphatase no greater than 2.5 times ULN

          -  Creatinine normal

          -  Creatinine clearance at least 60 mL/min

          -  No prior congestive heart failure requiring medication

          -  No uncontrolled hypertension within the past 6 months

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  No other invasive malignancies within the past 5 years except nonmelanoma skin cancer

          -  No history of retinopathy and/or macular degeneration

          -  No neuropathy (sensory and motor) greater than grade 1

          -  No active infection requiring antibiotics

          -  No other illness or condition that would preclude study entry

          -  No prior bone marrow or stem cell transplantation

          -  At least 3 weeks since prior biologic therapy or immunotherapy for malignant tumor

          -  One prior non-cytotoxic regimen (e.g., monoclonal antibodies, cytokines, or
             small-molecule signal transduction inhibitors) allowed

          -  See Disease Characteristics

          -  At least 3 weeks since prior chemotherapy and recovered

          -  No prior irofulven

          -  No additional prior cytotoxic chemotherapy for recurrent or persistent disease,
             including retreatment with initial chemotherapy regimens

          -  At least 1 week since prior hormonal therapy for malignant tumor

          -  Concurrent hormone replacement therapy allowed

          -  See Disease Characteristics

          -  At least 3 weeks since prior radiotherapy and recovered

          -  No prior radiotherapy to more than 25% of marrow-bearing areas

          -  Recovered from recent prior surgery

          -  At least 3 weeks since any other prior therapy for malignant tumor

          -  No prior anticancer treatment that would preclude study therapy

          -  One prior noncytotoxic cytostatic regimen for recurrent or persistent disease allowed
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Russell Schilder</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gynecologic Oncology Group</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Gynecologic Oncology Group</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <lastchanged_date>April 29, 2014</lastchanged_date>
  <firstreceived_date>January 27, 2003</firstreceived_date>
  <firstreceived_results_date>August 12, 2013</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Neoplasms, Glandular and Epithelial</mesh_term>
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Peritoneal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Irofulven</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Stage I of the study accrued patients from 6/2/2003 through 10/31/2005. Stage II of the study accrued patients from 1/3/2006 through 4/7/2008.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Treatment (Irofulven)</title>
          <description>Patients receive irofulven IV over 30 minutes on days 1 and 8. Courses repeat every 21 days in the absence of unacceptable toxicity or disease progression.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="61"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="55"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Incorrect cell type</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Platinum-sensitive interval &gt;12 months</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Never treated</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>This is the number of eligible and evaluable participants.</population>
      <group_list>
        <group group_id="B1">
          <title>Treatment (Irofulven)</title>
          <description>Patients receive irofulven IV over 30 minutes on days 1 and 8. Courses repeat every 21 days in the absence of unacceptable toxicity or disease progression.</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="55"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="59.2" spread="9.7"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>30-39 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>40-49 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="10"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>50-59 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="17"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>60-69 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="21"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>70-79 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="4"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>80-89 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="2"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="55"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="55"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Recurrent/Persistent Disease</title>
          <description>FIGO (International Federation of Gynecology and Obestetrics) Stage Grouping for Primary Carcinoma of the Ovary(1985)</description>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="55"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Cell Type</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Endometrioid Adenocarcinoma</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="2"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Mixed Epithelial Carcinoma</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="3"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Serous Adenocarcinoma</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="47"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Undifferentiated Carcinoma</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="3"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Tumor Response</title>
        <description>Per Gynecologic Oncology Group(GOG) Response Evaluation Criteria in Solid Tumors(RECIST) Criteria: Complete Response is disappearance of all target and non-target lesions; Partial Response is at least a 30% decrease in the sum of longest dimensions (LD) of all target measurable dimensions; Increasing Disease is at least a 20% increase in the sum of LD of target lesions taking as reference the smallest sum LD or the appearance of new lesions within 8 weeks of study entry.
Response is to be evaluated every 42 days for the first 6 months and every 6 months thereafter while the patient is receiving study treatment, then every 3 months for 2 years and every 6 months for the next 3 years until documented progression or death.</description>
        <time_frame>From entry into study until documented progression or death, assessed up to 5 years.</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Irofulven)</title>
            <description>Patients receive irofulven IV over 30 minutes on days 1 and 8. Courses repeat every 21 days in the absence of unacceptable toxicity or disease progression.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="55"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Tumor Response</title>
            <description>Per Gynecologic Oncology Group(GOG) Response Evaluation Criteria in Solid Tumors(RECIST) Criteria: Complete Response is disappearance of all target and non-target lesions; Partial Response is at least a 30% decrease in the sum of longest dimensions (LD) of all target measurable dimensions; Increasing Disease is at least a 20% increase in the sum of LD of target lesions taking as reference the smallest sum LD or the appearance of new lesions within 8 weeks of study entry.
Response is to be evaluated every 42 days for the first 6 months and every 6 months thereafter while the patient is receiving study treatment, then every 3 months for 2 years and every 6 months for the next 3 years until documented progression or death.</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Partial Response</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7" lower_limit="0.07" upper_limit="0.29"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Stable Disease</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="30"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Increase Disease</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="12"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Indeterminate</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Frequency and Severity of Observed Adverse Events, Graded According to the National Cancer Institute Common Toxicity Criteria (NCI CTC) v2.0</title>
        <time_frame>Up to 5 years</time_frame>
        <safety_issue>Yes</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival and Progression-free Survival</title>
        <description>Per Gynecologic Oncology Group(GOG) Response Evaluation Criteria in Solid Tumors(RECIST) Criteria, progression is defined as at least a 20% increase in the sum of longest dimesions(LD) of target lesions taking as reference the smallest sum LD or the appearance of new lesions within 8 weeks of study entry.</description>
        <time_frame>From entry into study to death or date of last contact, assessed up to 5 years</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Irofulven)</title>
            <description>Patients receive irofulven IV over 30 minutes on days 1 and 8. Courses repeat every 21 days in the absence of unacceptable toxicity or disease progression.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="55"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Overall Survival and Progression-free Survival</title>
            <description>Per Gynecologic Oncology Group(GOG) Response Evaluation Criteria in Solid Tumors(RECIST) Criteria, progression is defined as at least a 20% increase in the sum of longest dimesions(LD) of target lesions taking as reference the smallest sum LD or the appearance of new lesions within 8 weeks of study entry.</description>
            <units>months</units>
            <param>Median</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>Median Overall Survival</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="24.1" lower_limit="17.5" upper_limit="28.9"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Median Progression-free Survival</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6.7" lower_limit="4.1" upper_limit="8.9"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Progression-free Survival</title>
        <time_frame>From study entry until disease progression, death or date of last contact, assessed up to 5 years</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse Events(AEs) considered to be due to study treatment are to be reported up until 5 years after initiating treatment.</time_frame>
      <desc>A patient's AEs are reported following each cycle of study treatment and include AEs occurring within 30 days of each cycle.</desc>
      <group_list>
        <group group_id="E1">
          <title>Treatment (Irofulven)</title>
          <description>Patients receive irofulven IV over 30 minutes on days 1 and 8. Courses repeat every 21 days in the absence of unacceptable toxicity or disease progression.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (2.0)</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiovascular Other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Thrombosis Embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Ocular Other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Vision Photophobia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Vision Blurres</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Vomitting</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Gi Other</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection Without Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypomagnesmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle Weakness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Ataxia(Incoordination)</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Neuropathy Sensor</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (2.0)</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="55" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Transfusion Prbc's</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Sinus Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Edema</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hot Flashes/Flushes</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Ocular Other</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Dry Eye</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Vision Photophobia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Vision Flashing Lights/Floaters</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Vision Blurres</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Dyspepsia/Heartburn</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Dysphagia Esophagitis Odynophagia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Diarrhea Without Colostomy</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Stomatitis/Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Vomitting</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fever(No Neutropenia)</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Sweating</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Pain Other</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Sgot(Alt)</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Sgot(Ast)</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Alkaline Phosphatase</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection Without Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Hypomagnesmia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle Weakness</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Ataxia(Incoordination)</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Mood Alteration Depression</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Neuropathy Sensor</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary Retention</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Voice Changes/Stridor/Larynx</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Rash Desquamation</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Bruising</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hematuria No Vaginal Bleeding</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Melissa Leventhal</name_or_title>
      <organization>Gynecologic Oncology Group</organization>
      <phone>716-845-4030</phone>
      <email>mleventhal@gogstats.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
